News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Submit an Event
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
233,207 Results
Type
Article (23293)
Company Profile (44)
Press Release (209870)
Multimedia
Podcasts (31)
Webinars (6)
Section
Business (64044)
Career Advice (1369)
Deals (9514)
Drug Delivery (51)
Drug Development (27629)
Employer Resources (89)
FDA (5332)
Job Trends (6508)
News (108015)
Policy (10247)
Tag
2027 Genetown Elite (1)
2027 Pharm Country Elite (1)
2027 Pharm Country Standard (1)
Academia (1980)
Accelerated approval (13)
Adcomms (28)
Allergies (45)
Alliances (17456)
ALS (70)
Alzheimer's disease (759)
Antibody-drug conjugate (ADC) (106)
Approvals (5368)
Artificial intelligence (230)
Autoimmune disease (38)
Automation (12)
Bankruptcy (98)
Best Places to Work (5516)
BIOSECURE Act (17)
Biosimilars (52)
Biotechnology (28)
Bladder cancer (80)
Brain cancer (32)
Breast cancer (327)
Cancer (2154)
Cardiovascular disease (180)
Career advice (1159)
Career pathing (20)
CAR-T (116)
CDC (30)
Celiac Disease (1)
Cell therapy (304)
Cervical cancer (17)
Clinical research (22892)
Collaboration (618)
Company closure (1)
Compensation (93)
Complete response letters (28)
COVID-19 (1494)
CRISPR (42)
C-suite (345)
Cystic fibrosis (46)
Data (2247)
Decentralized trials (1)
Denatured (2)
Depression (63)
Diabetes (165)
Diagnostics (2635)
Digital health (15)
Diversity (5)
Diversity, equity & inclusion (30)
Drug discovery (106)
Drug pricing (85)
Drug shortages (12)
Duchenne muscular dystrophy (67)
Earnings (18256)
Editorial (42)
Employer branding (7)
Employer resources (86)
Events (29360)
Executive appointments (389)
FDA (6410)
Friedreich's ataxia (5)
Frontotemporal dementia (14)
Funding (825)
Gene editing (85)
Generative AI (21)
Gene therapy (287)
GLP-1 (338)
Government (2213)
Grass and pollen (3)
Guidances (140)
Healthcare (7732)
HIV (22)
Huntington's disease (17)
IgA nephropathy (40)
Immunology and inflammation (115)
Immuno-oncology (28)
Indications (33)
Infectious disease (1594)
Inflammatory bowel disease (67)
Inflation Reduction Act (5)
Influenza (30)
Intellectual property (59)
Interviews (268)
IPO (4424)
IRA (30)
Job creations (1084)
Job search strategy (948)
JPM (37)
Kidney cancer (9)
Labor market (45)
Layoffs (200)
Leadership (21)
Legal (2201)
Liver cancer (31)
Longevity (6)
Lung cancer (267)
Lymphoma (175)
Machine learning (17)
Management (32)
Manufacturing (282)
MASH (52)
Medical device (4817)
Medtech (4831)
Mergers & acquisitions (5463)
Metabolic disorders (435)
Multiple sclerosis (64)
NASH (6)
Neurodegenerative disease (135)
Neuropsychiatric disorders (47)
Neuroscience (1272)
Neurotech (1)
NextGen: Class of 2026 (2904)
Non-profit (2562)
Now hiring (16)
Obesity (195)
Opinion (191)
Ovarian cancer (67)
Pain (103)
Pancreatic cancer (85)
Parkinson's disease (107)
Partnered (21)
Patents (115)
Patient recruitment (162)
Peanut (14)
People (24970)
Pharmaceutical (12)
Pharmacy benefit managers (6)
Phase 1 (7167)
Phase 2 (10026)
Phase 3 (7712)
Pipeline (1749)
Policy (162)
Postmarket research (930)
Preclinical (3111)
Press Release (22)
Prostate cancer (96)
Psychedelics (30)
Radiopharmaceuticals (91)
Rare diseases (355)
Real estate (1951)
Recruiting (37)
Regulatory (7470)
Reports (15)
Research institute (2079)
Resumes & cover letters (217)
Rett syndrome (15)
RNA editing (7)
RSV (21)
Schizophrenia (61)
Series A (137)
Series B (86)
Service/supplier (1)
Sickle cell disease (51)
Special edition (9)
Spinal muscular atrophy (51)
Sponsored (14)
Startups (1759)
State (1)
Stomach cancer (11)
Supply chain (39)
Tariffs (46)
The Weekly (28)
Vaccines (462)
Venture capital (69)
Weight loss (139)
Women's health (37)
Worklife (13)
Date
Last 7 days (186)
Last 30 days (685)
Last 365 days (10031)
2026 (883)
2025 (10232)
2024 (11784)
2023 (13601)
2022 (17407)
2021 (19941)
2020 (19310)
2019 (18005)
2018 (13573)
2017 (11394)
2016 (11248)
2015 (12892)
2014 (9474)
2013 (7808)
2012 (8066)
2011 (8421)
2010 (7162)
Location
Africa (421)
Alabama (63)
Alaska (5)
Arizona (92)
Arkansas (7)
Asia (13021)
Australia (2858)
California (3204)
Canada (883)
China (290)
Colorado (168)
Connecticut (125)
Delaware (139)
Europe (30104)
Florida (554)
Georgia (135)
Hawaii (1)
Idaho (22)
Illinois (308)
India (21)
Indiana (158)
Iowa (9)
Japan (143)
Kansas (30)
Kentucky (19)
Louisiana (9)
Maine (42)
Maryland (398)
Massachusetts (2195)
Michigan (76)
Minnesota (210)
Mississippi (2)
Missouri (50)
Montana (18)
Nebraska (6)
Nevada (29)
New Hampshire (22)
New Jersey (1111)
New Mexico (9)
New York (1051)
North Carolina (499)
North Dakota (3)
Northern California (1488)
Ohio (103)
Oklahoma (11)
Oregon (13)
Pennsylvania (641)
Puerto Rico (4)
Rhode Island (25)
South America (494)
South Carolina (13)
Southern California (1272)
Tennessee (63)
Texas (1242)
United States (12909)
Utah (103)
Vermont (1)
Virginia (86)
Washington D.C. (43)
Washington State (297)
West Virginia (4)
Wisconsin (41)
233,207 Results for "texas back institute".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Mergers & acquisitions
Revolution Knows Its Worth as Merck Backs Off—For Now
Investors are apparently taking bets on when Revolution will be acquired. A handful of pharmas could be interested as Merck backs off.
January 26, 2026
·
4 min read
·
Annalee Armstrong
Press Releases
Texas Cardiac Arrhythmia Institute at St. David’s Medical Center first in U.S. to implant FDA-approved novel defibrillation lead
February 3, 2026
·
2 min read
Press Releases
Salarius Pharmaceuticals to Collaborate with Texas Biomedical Research Institute on Avian Flu Study
December 2, 2025
·
11 min read
Mergers & acquisitions
Merck Backs Off Revolution After Failing To Agree on Price: WSJ
Merck had previously offered anywhere from $28 billion to $32 billion to swallow Revolution Medicines.
January 26, 2026
·
1 min read
·
Tristan Manalac
Press Releases
Bavarian Nordic – Transactions in Connection with Share Buy-Back Program - February 2, 2026
February 2, 2026
·
2 min read
Rare diseases
GSK Hands RNA Editor Back to Wave After Underwhelming Early AATD Data
While GSK did not provide a specific reason for returning Wave Life Sciences’ WVE-006, the decision comes after the asset in September 2025 came below analyst expectations in a Phase Ib/IIa AATD study.
February 2, 2026
·
2 min read
·
Tristan Manalac
Press Releases
Bavarian Nordic Launches Planned Share Buy-Back Program
January 7, 2026
·
2 min read
Deals
With Biotech Back, Analysts Make Their Picks for 2026
The second half finished strong after two tumultuous years. What will 2026 bring for the biotech sector?
December 22, 2025
·
2 min read
·
Annalee Armstrong
Approvals
Sentynl, Fortress Bounce Back With FDA Approval for Rare Pediatric Disease
The FDA previously rejected Zycubo for Menkes disease in October last year, citing issues with the drug’s manufacturing facility.
January 13, 2026
·
2 min read
·
Tristan Manalac
Press Releases
Bavarian Nordic – Transactions in Connection with Share Buy-Back Program - January 19, 2026
January 20, 2026
·
2 min read
1 of 23,321
Next
